LENZ Therapeutics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 LENZ Therapeutics Inc 公司

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

LENZ Therapeutics Inc简介



公司代码LENZ

公司名称LENZ Therapeutics Inc

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

员工数量42

证券类型Ordinary Share

年结日Jun 25

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

国家- -

邮编- -

电话- -

网址- -

公司代码LENZ

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

LENZ Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. James Mccollum

Independent Director

631.10K

+10500.00%

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

5.39K

+2198.00%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Ms. Shelley B. Thunen

Independent Director

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. James Mccollum

Independent Director

631.10K

+10500.00%

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

5.39K

+2198.00%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 2月1日周日

持股股东

股东类型

持股股东

占比

RA Capital Management, LP

13.36%

Alpha Wave Global, LP

11.54%

Versant Ventures

8.49%

Ridgeback Capital Management, L.P.

6.24%

UBS Financial Services, Inc.

5.02%

其他

55.35%

持股股东

占比

RA Capital Management, LP

13.36%

Alpha Wave Global, LP

11.54%

Versant Ventures

8.49%

Ridgeback Capital Management, L.P.

6.24%

UBS Financial Services, Inc.

5.02%

其他

55.35%

股东类型

持股股东

占比

Venture Capital

34.63%

Investment Advisor

30.67%

Hedge Fund

23.82%

Investment Advisor/Hedge Fund

17.10%

Individual Investor

2.52%

Research Firm

2.00%

Pension Fund

0.23%

Bank and Trust

0.13%

Insurance Company

0.02%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

309

33.95M

108.49%

+1.00M

2025Q3

267

30.95M

100.67%

+981.38K

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RA Capital Management, LP

4.18M

14.65%

--

Jun 30, 2025

Alpha Wave Global, LP

3.61M

12.66%

--

Jun 30, 2025

Versant Ventures

2.88M

10.1%

-135.30K

-4.48%

Sep 18, 2025

Ridgeback Capital Management, L.P.

1.95M

6.84%

--

Apr 14, 2025

UBS Financial Services, Inc.

881.48K

3.09%

+214.32K

+32.12%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.27M

4.44%

+216.45K

+20.60%

Jun 30, 2025

The Vanguard Group, Inc.

1.29M

4.52%

+91.53K

+7.65%

Jun 30, 2025

Paradigm BioCapital Advisors LP

1.72M

6.02%

+297.23K

+20.93%

Jun 30, 2025

72 Investment Holdings, LLC

1.02M

3.57%

--

Jun 30, 2025

Tang Capital Management, LLC

897.62K

3.15%

+130.68K

+17.04%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.27%

iShares U.S. Pharmaceuticals ETF

0.22%

ProShares Ultra Nasdaq Biotechnology

0.11%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.08%

iShares Biotechnology ETF

0.06%

State Street SPDR S&P Pharmaceuticals ETF

占比1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.04%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.27%

iShares U.S. Pharmaceuticals ETF

占比0.22%

ProShares Ultra Nasdaq Biotechnology

占比0.11%

iShares Micro-Cap ETF

占比0.09%

Invesco Nasdaq Biotechnology ETF

占比0.08%

iShares Biotechnology ETF

占比0.06%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

公告日期

除权除息日

类型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1